Automated Oxygen Administration Alleviates Dyspnea in Patients Admitted with Acute Exacerbation of COPD: A Randomized Controlled Trial
Charlotte Sandau,Ejvind Frausing Hansen,Thomas Jørgen Ringbæk,Thomas Kallemose,Dorthe Gaby Bove,Ingrid Poulsen,Vibeke Nørholm,Lars Pedersen,Jens Ulrik Stæhr Jensen,Charlotte Suppli Ulrik
DOI: https://doi.org/10.2147/COPD.S397782
2023-04-19
International Journal of COPD
Abstract:Charlotte Sandau, 1 Ejvind Frausing Hansen, 1 Thomas Jørgen Ringbæk, 2 Thomas Kallemose, 3 Dorthe Gaby Bove, 4 Ingrid Poulsen, 3, 5 Vibeke Nørholm, 3 Lars Pedersen, 6 Jens Ulrik Stæhr Jensen, 7, 8 Charlotte Suppli Ulrik 1, 9 1 Department of Respiratory Medicine and Endocrinology, Pulmonary Section, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark; 2 Allergy and Lung Clinic, Elsinore, Denmark; 3 Department of Clinical Research, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark; 4 University College Absalon, Centre for Nursing, Roskilde, Denmark; 5 Research Unit Nursing and Health Care, Aarhus University, Aarhus, Denmark; 6 Department of Respiratory Medicine and Infectious Diseases, Copenhagen University Bispebjerg Hospital, Copenhagen, Denmark; 7 Respiratory Medicine Section, Department of Medicine, Herlev-Gentofte Hospital, Hellerup, Denmark; 8 Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, København, Denmark; 9 Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark Correspondence: Charlotte Sandau, Email Objective: Devices for Automated Oxygen Administration (AOA) have been developed to optimize the therapeutic benefit of oxygen supplementation. We aimed to investigate the effect of AOA on multidimensional aspects of dyspnea and as-needed consumption of opioids and benzodiazepines, as opposed to conventional oxygen therapy, in hospitalized patients with Acute Exacerbation of COPD (AECOPD). Method and Patients: A multicenter randomized controlled trial across five respiratory wards in the Capital Region of Denmark. Patients admitted with AECOPD (n=157) were allocated 1:1 to either AOA (O2matic Ltd), a closed loop device automatically delivering oxygen according to the patient's peripheral oxygen saturation (SpO 2 ), or conventional nurse-administered oxygen therapy. Oxygen flows and SpO 2 levels were measured by the O2matic device in both groups, while dyspnea, anxiety, depression, and COPD symptoms were accessed by Patient Reported Outcomes. Results: Of the 157 randomized patients, 127 had complete data for the intervention. The AOA reduced patients' perception of overall unpleasantness significantly on the Multidimensional Dyspnea Profile (MDP) with a difference in medians of − 3 ( p =0.003) between the intervention group (n=64) and the control group (n=63). The AOA also provided a significant between group difference in all single items within the sensory domain of the MDP (all p -values≤ 0.05) as well as in the Visual Analogue Scale – Dyspnea (VAS-D) within the past three days ( p =0.013). All between group differences exceeded the Minimal Clinical Important Difference of the MDP and VAS-D, respectively. AOA did not seem to have an impact on the emotional response domain of the MDP, the COPD Assessment Test, the Hospital Anxiety and Depression Scale, or use of as-needed opioids and/or benzodiazepines (all p -values> 0.05). Conclusion: AOA reduces both breathing discomfort and physical perception of dyspnea in patients admitted with AECOPD but did not seem to impact the emotional status or other COPD symptoms. Keywords: dyspnea, oxygen, automated oxygen therapy, multidimensional dyspnea profile, COPD, hospital, admission, therapy In patients with Chronic Obstructive Pulmonary Disease (COPD), acute exacerbations are a major cause of hospitalizations, and in most cases associated with dyspnea, anxiety, and hypoxemia. 1,2 Supplemental oxygen is a key component of the in-hospital management of these patients. Titrated oxygen therapy to achieve oxygen saturation (SpO 2 ) between 88 and 92% reduces the risk of hypercapnic acidosis and the need for assisted ventilation compared to higher flow rates, reaching higher SpO 2 levels. 3,4 To optimize the administration of oxygen and thereby therapeutic impact, devices with Automatic Oxygen Administration (AOA), in response to the patient's SpO 2 , have been developed. 5,6 It has been shown that AOA significantly increases the proportion of time within the guideline-recommended ranges of SpO 2 compared to conventional oxygen therapy. 5–8 Dyspnea is often associated with hypoxemia and is a major cause of suffering and therefore a treatment target. The clinical management of Acute Exacerbation in COPD (AECOPD) is complex and includes inhaled bronchodilators and oxygen therapy for hypoxemic patients. To reduce the intensity of dyspnea, these primary therapies m -Abstract Truncated-
respiratory system